FYB202 is an interleukin inhibitor that can be used in dermatology to treat psoriasis and in gastroenterology to treat chronic inflammatory bowel disease. The biosimilar received marketing ...

Scientific publicationFormycon presents clinical data on ustekinumab biosimilar FYB202 at the ECCO Congress in Berlin 20.02.2025 / 06:30 CET/CESTThe issuer is solely responsible for the content of ...

Several species of the genus Euphorbia (Eu-phorbiaceae) have been tested for their efficiency as antiviral and antitumour agents, partly based on information concerning plants that have traditionally ...

Isatin is still considered to be a promising agent during the planning of new drugs given its low production costs and its chemical structure. The possibility to introduce diverse chemical ...

Conventional bioassays like ELISA have relied on enzyme or fluorescent labels to detect and monitor biomolecular interactions; however, these labels can introduce artefacts, complicating data ...

Increasing anthropogenic CO 2 emissions in recent decades cause ocean acidification (OA), affecting carbon cycling in oceans by regulating eco-physiological processes of plankton. Heterotrophic ...